The level of anti-inflammatory cytokine IL-10 in patients with chronic obstructive pulmonary disease of varying severity

Imbalance in the system cytokines in patients with COPD is an important pathogenic mechanism of development and progression of chronic persistent inflammation. Purpose: To study the level of anti-inflammatory cytokine IL-10 in bronchial secretions and serum of patients with COPD of varying severity, to analyze the effect of anti-inflammatory therapy. We examined 112 patients with COPD of varying severity. The greatest value of IL-10 was detected in patients with mild COPD (26,72 ± 3,48 pg / ml in sputum, 13,43 ± 0,17 pc / ml in bronchial washings, 19,03 ± 1,39 pg / ml in serum compared with more severe. With increasing severity of COPD, the level of IL-10 decreased in all body fluids: for very severe COPD level of IL-10 in sputum 16,42 ± 6,06 pg / ml washes bronchial 0,38 ± 0,12 pg / ml (p There was a negative correlation between the level of IL-8 and IL-10 sputum (r = -0, 40, p = 0.008), with increased activity of the inflammatory cytokine IL-8 level reduced and IL-10. The level of IL-10 in sputum, bronchial lavage and serum of patients who had not received inhaled corticosteroids did not differ significantly from the level of IL-10 patients received inhaled anti-inflammatory therapy. Conclusion: Receiving inhaled glucocorticosteroids does not affect the anti-inflammatory cytokine IL-10 directly, but it can have an indirect effect, reducing the activity of pro-inflammatory cytokines. High activity of pro-inflammatory cytokines in severe COPD may inhibit the synthesis of IL-10.